Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833766 | 0.95 | PARP14 (0.43) | LMNAPARP14ALDH1A1KDM4EPKM | |
| SCHEMBL6834079 | 0.93 | NHERF1 (0.44) | LMNAPARP14ALDH1A1KDM4EMEN1 | |
| SCHEMBL6834072 | 0.93 | ALDH1A1 (0.41) | LMNAPARP14ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6835671 | 0.93 | LMNA (0.39) | LMNAPARP14PKMRXFP1ALB | |
| SCHEMBL6834298 | 0.93 | MEN1 (0.44) | LMNAPARP14ALDH1A1KDM4EPKM | |
| SCHEMBL6833973 | 0.92 | PARP14 (0.42) | LMNAPARP14PKMRXFP1ALB | |
| SCHEMBL6833821 | 0.92 | NHERF1 (0.43) | LMNAPARP14KDM4EMEN1KMT2A | |
| SCHEMBL6833157 | 0.92 | PARP14 (0.42) | LMNAPARP14ALDH1A1KDM4EPKM | |
| SCHEMBL6833683 | 0.91 | NR1H4 (0.48) | ALDH1A1 | |
| SCHEMBL6833337 | 0.91 | RXFP1 (0.45) | LMNAPARP14RXFP1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | LMNA 3376/4885PARP14 2395/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.